

1 **Metabolomic Age (MileAge) predicts health and lifespan: a**
2 **comparison of multiple machine learning algorithms**

3

4 **Short title:** Metabolomic MileAge UK Biobank

5

6 **Authors:** Julian Mutz^{1*}, Raquel Iniesta² and Cathryn M Lewis^{1,3}

7

8 **Affiliations:**

- 9 1. Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,
10 Psychology & Neuroscience, King's College London, London, United Kingdom.
11 2. Department of Biostatistics and Health Informatics, King's College London, London,
12 United Kingdom.
13 3. Department of Medical and Molecular Genetics, Faculty of Life Sciences &
14 Medicine, King's College London, London, United Kingdom.

15

16 ***Corresponding author:**

17 Julian Mutz, PhD; Social, Genetic and Developmental Psychiatry Centre, Institute of
18 Psychiatry, Psychology & Neuroscience, King's College London, Memory Lane, London,
19 SE5 8AF, United Kingdom. Email: julian.mutz@gmail.com.

20 **Abstract**

21 **Background:** Molecular ageing clocks estimate an individual's biological age. Our aim was
22 to compare multiple machine learning algorithms for developing ageing clocks from nuclear
23 magnetic resonance (NMR) spectroscopy metabolomics data. To validate how well each
24 ageing clock predicted age-related morbidity and lifespan, we assessed their associations with
25 multiple health indicators (e.g., telomere length and frailty) and all-cause mortality.

26 **Methods:** The UK Biobank is a multicentre observational health study of middle-aged and
27 older adults. The Nightingale Health platform was used to quantify 168 circulating plasma
28 metabolites at the baseline assessment from 2006 to 2010. We trained and internally
29 validated 17 machine learning algorithms including regularised regression, kernel-based
30 methods and ensembles. Metabolomic age (MileAge) delta was defined as the difference
31 between predicted and chronological age.

32 **Results:** The sample included 101,359 participants (mean age = 56.53 years, SD = 8.10).
33 Most metabolite levels varied by chronological age. The nested cross-validation mean
34 absolute error (MAE) ranged from 5.31 to 6.36 years. 31.76% of participants had an age-bias
35 adjusted MileAge more than one standard deviation (3.75 years) above or below the mean. A
36 Cubist rule-based regression model overall performed best at predicting health outcomes. The
37 all-cause mortality hazard ratio (HR) comparing individuals with a MileAge delta more than
38 one standard deviation above and below the mean was HR = 1.52 (95% CI 1.41-1.64, $p <$
39 0.001) over a median follow-up of 13.87 years. Individuals with an older MileAge were
40 frailer, had shorter telomeres, were more likely to have a chronic illness and rated their health
41 worse.

42 **Conclusions:** Metabolomic ageing clocks derived from multiple machine learning algorithms
43 were robustly associated with health indicators and mortality. Our metabolomic ageing clock
44 (MileAge) derived from a Cubist rule-based regression model can be incorporated in
45 research, and may find applications in health assessments, risk stratification and proactive
46 health tracking.

47

48 **Keywords:** ageing clocks; biological age; biomarkers; machine learning; metabolomics

49 **Introduction**

50 Chronological age, the time elapsed since birth, is a powerful predictor of health and disease
51 (Mutz, Roscoe, & Lewis, 2021). However, there is considerable heterogeneity in health
52 status, lifestyle and the physical signs of ageing between individuals of the same
53 chronological age. This variability may partly reflect individual differences in biological
54 ageing, which is the process of accumulating molecular and cellular damage that results in a
55 progressive decline in physiological functioning (Moqri et al., 2023). While our
56 chronological age cannot be altered, biological ageing trajectories in humans may be
57 modifiable, or even reversible. Therefore, developing reliable measures of biological age is
58 an important priority in biomedical research and population health.

59
60 Although there is no single biological marker of biological ageing, several hallmarks such as
61 telomere length shortening have been identified (López-Otín, Blasco, Partridge, Serrano, &
62 Kroemer, 2023). Clinical and population studies of age-related biological changes have also
63 examined physiological measures of grip strength and cardiovascular function (Mutz,
64 Hoppen, Fabbri, & Lewis, 2022; Mutz & Lewis, 2021; Mutz, Young, & Lewis, 2022), blood-
65 based biomarkers (Nakamura, Miyao, & Ozeki, 1988), inflammatory markers (Franceschi,
66 Garagnani, Parini, Giuliani, & Santoro, 2018) and frailty (Hoogendijk et al., 2019).

67
68 Molecular “omics” and neuroimaging data such as DNA methylation (Hannum et al., 2013;
69 Horvath & Raj, 2018; Lu et al., 2019) and structural magnetic resonance imaging (Cole &
70 Franke, 2017) have facilitated the development of biological ageing clocks (Rutledge, Oh, &
71 Wyss-Coray, 2022; Solovev, Shaposhnikov, & Moskalev, 2020). Ageing clocks are usually
72 developed using machine learning algorithms that identify relationships between
73 chronological age and molecular data. The difference between predicted age, which
74 approximates biological age, and chronological age is associated with health outcomes
75 (Macdonald-Dunlop et al., 2022). Ageing clocks provide a more holistic picture of a person’s
76 health and are conceptually easier to understand than most individual molecular markers as
77 they are expressed in unit of years.

78
79 Population-scale metabolomics, the study of small molecules, i.e., metabolites, within cells,
80 tissues or organisms, is increasingly incorporated into biological ageing research (Panyard,
81 Yu, & Snyder, 2022). Metabolites are the products of metabolism, for example when food is

82 converted to energy. While many initial metabolomics studies were limited to few
83 metabolites and small samples, technological advancements have enabled the population-
84 scale profiling of multiple molecular pathways (Soininen, Kangas, Würtz, Suna, & Ala-
85 Korpela, 2015). Simultaneously quantifying hundreds or thousands of metabolites can
86 provide unprecedented snapshots of an individual's physiological state. Metabolomic profiles
87 predict many common incident diseases (Buergel et al., 2022) and mortality risk (Deelen et
88 al., 2019). Over the past decade, studies have characterised associations between
89 chronological age and metabolomic biomarkers (Lawton et al., 2008; Menni et al., 2013; Yu
90 et al., 2012). The first study to develop a "metabolite-derived age variable" showed that a
91 panel of 22 metabolites explained 59% of the variance in chronological age. A linear
92 combination of these metabolites was correlated with age-related clinical measures
93 independent of chronological age (Menni et al., 2013). The first study to develop a biological
94 ageing clock from metabolomics data showed that the difference between predicted and
95 chronological age, metabolomic age delta, was associated with a higher disease burden and
96 higher mortality (Hertel et al., 2016). Analyses in other samples, for example the Airwave
97 Health Monitoring Study in the UK (Robinson et al., 2020) and the Dutch BBMRI-NL
98 consortium (van den Akker et al., 2020), have since replicated some of these findings.
99 Metabolomics is amongst the most powerful omics data for biological age estimation
100 (Solovev et al., 2020) and prediction of disease (Macdonald-Dunlop et al., 2022).

101

102 The aim of this study was to compare multiple machine learning algorithms for developing
103 ageing clocks from nuclear magnetic resonance (NMR) spectroscopy metabolomics data in
104 more than 100,000 participants in the UK Biobank (Bycroft et al., 2018). These data provide
105 an unprecedented resource to develop ageing clocks and represent one of the largest single
106 NMR metabolomics databases to date. To validate how well each ageing clock predicted age-
107 related morbidity and lifespan, and captured biological signal beyond that approximated by
108 chronological age (Hertel et al., 2019), we assessed their associations with multiple health
109 indicators (e.g., telomere length and frailty) and all-cause mortality.

110 **Methods**

111 **Study population**

112 The UK Biobank is a prospective health study of over 500,000 UK residents aged 37–73 who
113 were recruited between 2006 and 2010. Individuals registered with the UK National Health
114 Service (NHS) and living within a 25-mile (~40 km) radius of one of 22 assessment centres
115 were invited to participate (Bycroft et al., 2018). Participants provided data on their
116 sociodemographic characteristics, health behaviours and medical history, underwent physical
117 examination and had blood and urine samples taken. There is extensive record linkage, for
118 example with national death registries, hospital inpatient records and primary care data.

119

120 **Metabolomic biomarker quantification**

121 Nuclear magnetic resonance (NMR) spectroscopy metabolomic biomarkers were quantified
122 in non-fasting blood plasma samples taken at the baseline assessment. The Nightingale
123 Health platform ascertains 168 circulating metabolites using a high-throughput standardized
124 protocol for sample quality control, preparation, data storage and automated analyses (Würtz
125 et al., 2017). The metabolites span multiple pathways, including lipoprotein lipids in 14
126 subclasses, circulating fatty acids and fatty acid compositions, as well as low-molecular
127 weight metabolites, such as amino acids, ketone bodies and glycolysis metabolites. Most
128 measures are highly correlated ($r > 0.9$) with routine clinical chemistry assays (Würtz et al.,
129 2017). For further details on sample preparation and quality control procedures, see
130 https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/nmrm_companion_doc.pdf. We used the first
131 release of metabolomics data (March 2021) on a random subset of 118,019 participants.

132

133 **Machine learning**

134 We evaluated 17 machine learning algorithms, including regularised linear regression, latent
135 variable modelling, instance-based learning, non-parametric regression, kernel-based
136 methods, tree-based models, rule-based models and ensemble methods (Panel 1). To
137 internally validate each algorithm in predicting chronological age from plasma metabolites,
138 we implemented 10×5 nested cross-validation (Figure 1a). Nested cross-validation is
139 preferred for internal validation over other existing approaches as it provides more accurate
140 error estimation (Bates, Hastie, & Tibshirani). We split the data into 10 folds of equal size, to
141 which individuals were allocated at random while preserving the chronological age
142 distribution of the full analytical sample (Figure 1b).

143 **Panel 1.** Overview of the machine learning algorithms used in this study.

144

145 Ridge regression: linear regression model with a penalty term (L_2 regularization) to shrink the
146 magnitude of coefficient estimates towards zero (Hoerl & Kennard, 1970).

147

148 Least Absolute Shrinkage and Selection Operator (LASSO): linear regression model with a
149 penalty term (L_1 regularization) to shrink the magnitude of coefficient estimates towards
150 zero. This technique can result in sparse models as variable selection is performed by
151 reducing some coefficient estimates exactly equal to zero (Tibshirani, 1996).

152

153 Elastic net: linear regression model that combines the L_1 and L_2 penalty terms of LASSO and
154 Ridge regression. This technique reduces the magnitude of some coefficient estimates
155 towards zero and can perform variable selection by reducing some coefficient estimates
156 exactly equal to zero (Zou & Hastie, 2005).

157

158 Partial least squares regression (PLSR): latent variable model that extracts a set of latent
159 factors that best explain the covariance between the predictors and outcome. These factors
160 are then used as predictors in a linear regression model (Wold, Sjöström, & Eriksson, 2001).

161

162 K-nearest neighbors (KNN): instance-based learning model which uses the weighted average
163 outcome of the k nearest data points to make predictions. In this context, “nearest” is usually
164 determined by a distance metric such as the Minkowski distance (Cover & Hart, 1967).

165

166 Multivariate adaptive regression splines (MARS): non-parametric regression model that
167 creates piecewise linear approximations of the relationship between the predictors and
168 outcome. This technique can model non-linear associations and interactions between the
169 predictors (J. Friedman, H., 1991).

170

171 MARS ensemble: ensemble method that combines the predictions of multiple MARS models
172 to improve the predictive accuracy and stability of the model (Kuhn & Johnson, 2013a).

173

174 Support vector regression (SVR): kernel-based method that seeks to identify a hyperplane
175 that best models the relationships between the predictors and outcome. This variation of the
176 support vector machine algorithm (Boser, Guyon, & Vapnik, 1992) was adapted for

177 regression and can employ a range of kernels to transform the data to a higher-dimensional
178 space, allowing for complex non-linear associations (Drucker, Burges, Kaufman, Smola, &
179 Vapnik, 1996). We tested linear, polynomial and radial basis function kernels.

180

181 Regression tree: technique that models the relationship between the predictors and outcome
182 by creating a tree-like structure of decision rules based on values of the predictors. Decision
183 trees are interpretable and can incorporate non-linear relationships and higher-order
184 interactions in the data (Breiman, Friedman, Olshen, & Stone, 1984).

185

186 Bagging: ensemble method that combines the predictions of multiple regression trees.
187 Bootstrapped aggregating (“bagging”) involves training regression trees on multiple,
188 randomly selected (“bootstrapped”) samples of the data. Bagging can improve the stability
189 and accuracy of decision tree models (Breiman, 1996).

190

191 Random forest: ensemble method that combines predictions of multiple regression trees.
192 Each tree is trained on a random subset of the data and, at each split, a subset of predictors,
193 reducing the correlation between decision trees in the ensemble (Breiman, 2001).

194

195 Extreme gradient boosting (XGBoost): ensemble method that builds decision trees
196 sequentially by implementing a gradient descent algorithm that seeks to minimize errors from
197 previous models while increasing the influence (“boosting”) of highly predictive models.
198 More complex models are penalised through L_1 and L_2 regularization to avoid overfitting (T.
199 Chen & Guestrin, 2016).

200

201 Bayesian additive regression trees (BART): ensemble method that uses Bayesian techniques
202 to iteratively construct and update multiple decision trees. Regularization priors force each
203 tree to explain only a subset of the relationship between the predictors and outcome, thereby
204 preventing overfitting (Chipman, George, & McCulloch, 2010).

205

206 Cubist rule-based regression: ensemble model that that derives rules from decision trees and
207 fits linear regression models for the subset of the data defined by each rule. The model
208 incorporates boosting techniques and may adjust predictions based on k -nearest neighbors
209 (Kuhn & Johnson, 2013b; Quinlan, 1992).

210

211 **RuleFit ensemble**: ensemble method that uses a tree-based model (XGBoost) to predict an
212 outcome and subsequently derives rules. LASSO is then used to select the most predictive
213 rules, resulting in a sparse linear model (J. H. Friedman & Popescu, 2008).

214

215 For each iteration of the outer loop of the nested cross-validation, 9/10 folds combined served
216 as the training set and the tenth fold served as the test set. The 90% training sets were further
217 divided into five equal size sets, and we performed 5-fold cross validation to empirically
218 identify, for each algorithm, the hyperparameter combination that resulted in the lowest
219 cross-validation mean absolute error (MAE). Tuning grids were set up using a maximum
220 entropy space-filling design. The size of each tuning grid was determined by the number of
221 available hyperparameters, type of hyperparameter (continuous, discrete or categorical) and
222 computational constraints. We tested up to ten values for each hyperparameter, resulting in
223 tuning grid sizes between ten (for Ridge regression) and 3125 (for XGBoost). Further details,
224 including pre-processing requirements, are available in [Table S1](#). The model specifications
225 with the lowest 5-fold cross-validation MAE were subsequently fit in the 90% training sets,
226 and performance was assessed by calculating the MAE, root-mean-square error (RMSE),
227 Pearson correlation coefficient (r) and the coefficient of determination (R^2) in the 10% test
228 sets. We also examined the average magnitude of discrepancy in predictive performance
229 between the training and test sets, extrapolation beyond the chronological age range in the
230 data and the computing hours required for hyperparameter tuning for each model.

231

232 **Metabolomic ageing clocks**

233 Individual-level age predictions for all participants were obtained by aggregating the
234 predictions of the ten test sets of the outer loop of the nested cross-validation. Metabolomic
235 age delta (MileAge delta) was calculated as the difference between predicted and
236 chronological age, with positive values representing an older predicted than chronological
237 age and negative values representing a younger predicted than chronological age. Given that
238 ageing clocks overestimate age in young individuals and underestimate age in older
239 individuals, we regressed predicted age (MileAge) on chronological age and used the
240 resulting intercept (β) and slope coefficient (α) estimates to apply a statistical correction to
241 the age prediction: MileAge (age bias adjusted) = MileAge + [Age - ($\alpha \times$ Age + β)] (de
242 Lange & Cole, 2020).

243 **Health indicators and mortality**

244 We tested associations between MileAge delta (adj.) and multiple health indicators: having a
245 long-standing illness, disability or infirmity (yes/no), self-rated health (“poor”, “fair”, “good”
246 or “excellent”) and overall health status (unhealthy/healthy) derived from 81 cancer and 443
247 non-cancer illnesses (Mutz & Lewis, 2022; Mutz et al., 2021). Next we examined
248 associations with the frailty phenotype and frailty index (Mutz, Choudhury, Zhao, & Dregan,
249 2022). The frailty phenotype summarises data on weight loss, exhaustion, physical activity,
250 walking speed and hand-grip strength. The frailty index was derived from 49 variables
251 obtained at the baseline assessment, including cardiometabolic, cranial, immunological,
252 musculoskeletal, respiratory and sensory traits, well-being, infirmity, cancer and pain. We
253 also tested associations between MileAge delta (adj.) and telomere length, measured using a
254 validated quantitative polymerase chain reaction assay that expresses telomere length as the
255 ratio of the telomere repeat copy number (T) relative to a single-copy gene (S) that encodes
256 haemoglobin subunit beta. T/S ratio is proportional to an individual’s average telomere length
257 (Lai, Wright, & Shay, 2018). Finally, we examined prospective associations with all-cause
258 mortality. The date of death was obtained through linkage with national death registries, NHS
259 Digital (England and Wales) and the NHS Central Register (Scotland). The censoring date
260 was 30 November 2022.

261

262 **Exclusion criteria**

263 Women who were pregnant or unsure that they were pregnant at the time of assessment were
264 excluded from the analysis given that their metabolite profiles likely changed during
265 pregnancy. Participants for whom their genetic and self-reported sex did not match were also
266 excluded as this may indicate poor data quality. We also excluded individuals with missing
267 metabolite data or potential outlier metabolite values, defined as values $4\times$ the interquartile
268 range (IQR) above or below the median.

269

270 **Statistical analyses**

271 All data processing and analyses were performed in R (version 4.2).

272

273 Sample characteristics were summarised using means and standard deviations or counts and
274 percentages. Generalised additive models were used to explore the relationship between
275 chronological age and metabolite levels. We further conducted metabolome-wide association
276 analyses of chronological age and all-cause mortality to identify metabolites that were

277 statistically significantly associated with chronological age and mortality (at $P < 0.05/168$).

278 Correlations between the predicted age derived from each machine learning model were

279 estimated using Pearson's correlation coefficient.

280

281 Cross-sectional associations between MileAge delta (adj.) and the frailty index and telomere

282 length were estimated using ordinary least squares regression. Associations between MileAge

283 delta and having a long-standing illness and overall health status were estimated using

284 logistic regression. Association between MileAge delta and the frailty phenotype and self-

285 rated health were estimated using ordinal logistic regression. For each health indicator, higher

286 values corresponded to worse health. For the health association analyses, we fitted minimally

287 adjusted models that included chronological age and sex as covariates. For the prospective

288 analyses of all-cause mortality, we calculated person-years of follow-up and the median

289 duration of follow-up of censored individuals. Survival probabilities by MileAge delta were

290 estimated using the Kaplan-Meier (KM) method (Kaplan & Meier, 1958) and we calculated

291 log-rank p -values. Hazard ratios (HRs) and 95% confidence intervals were estimated using

292 Cox proportional hazards models (Cox, 1972). Age in years was used as the underlying time

293 axis, with age 40 as the start of follow-up. Across both cross-sectional and prospective

294 analyses, we defined MileAge delta subgroups by standard deviation from the mean.

295 Individuals with a MileAge delta equal to or smaller than one standard deviation below the

296 mean were the reference group. To discern how this analytical decision might impact results,

297 and to enable comparability with other studies, we also report associations with all-cause

298 mortality for all models with subgroups defined by the bottom and top 10% of the

299 distribution as well as negative and positive values. Finally, we used generalised additive

300 models and spline functions to explore the relationship between MileAge delta as a

301 continuous variable and health indicators and all-cause mortality, respectively.

302

303 For the Cubist rule-based regression model, which across most analyses performed best at

304 predicting health outcomes, we performed additional analyses. We calculated variable

305 importance scores to identify metabolites that strongly contributed to MileAge. We explored

306 associations between MileAge delta and all-cause mortality stratified by sex, self-rated health

307 and chronological age group (39-49, 50-59 and 60-71 years). Finally, we assessed the

308 performance of our ageing clock by benchmarking it against other ageing markers: (a) we

309 estimated the hazard ratio for all-cause mortality by MileAge delta and other ageing marker

310 (grip strength, telomere length and the frailty index) subgroups defined by standard deviation

311 from the mean, adjusted for chronological age and sex; (b) we calculated the C-index and
312 95% confidence intervals for chronological age + sex (as the base model) and for each ageing
313 marker added separately to the model, with time (in days) since the baseline assessment as
314 the underlying time axis.

315 Results

316 Sample characteristics

317 Of the 118,019 participants with metabolomics data, 110,730 had complete information on all
 318 metabolites (Figure S1). After removing individuals with potential outlier metabolite values,
 319 inconsistencies between self-reported and genetic sex or possible pregnancies, the analytical
 320 sample included 101,359 participants (Table 1). The mean chronological age was 56.44 years
 321 (SD = 8.12), with the most common age being 61 years (Figure 1b). Most metabolite levels
 322 varied by chronological age (Figure 1c), showing considerable evidence of non-linear
 323 relationships (Figures S2-S33).
 324

Table 1. Sample characteristics

	MileAge delta (adj.)			
	Full sample (N=101359)	≤ 1SD below the mean (n=16204)	Middle (n=69166)	≥ 1SD above the mean (n=15989)
Age; mean (SD)	56.44 (8.12)	55.85 (8.33)	56.75 (8.08)	55.69 (8.00)
Sex				
Female	54484 (53.8%)	8062 (49.8%)	37002 (53.5%)	9420 (58.9%)
Male	46875 (46.2%)	8142 (50.2%)	32164 (46.5%)	6569 (41.1%)
Ethnicity				
White	95672 (94.4%)	15163 (93.6%)	65486 (94.7%)	15023 (94.0%)
Mixed-race	574 (0.6%)	103 (0.6%)	386 (0.6%)	85 (0.5%)
Black	1529 (1.5%)	233 (1.4%)	975 (1.4%)	321 (2.0%)
Asian	1953 (1.9%)	375 (2.3%)	1265 (1.8%)	313 (2.0%)
Chinese	291 (0.3%)	77 (0.5%)	184 (0.3%)	30 (0.2%)
Other	880 (0.9%)	173 (1.1%)	564 (0.8%)	143 (0.9%)
Missing ¹	460 (0.5%)	80 (0.5%)	306 (0.4%)	74 (0.5%)
Highest qualification				
None	17084 (16.9%)	2551 (15.7%)	11868 (17.2%)	2665 (16.7%)
O levels/GCSEs/CSEs	27008 (26.6%)	4237 (26.1%)	18435 (26.7%)	4336 (27.1%)
A levels/NVQ/HND/HNC ²	23235 (22.9%)	3637 (22.4%)	15961 (23.1%)	3637 (22.7%)
Degree	32826 (32.4%)	5577 (34.4%)	22091 (31.9%)	5158 (32.3%)
Missing ¹	1206 (1.2%)	202 (1.2%)	811 (1.2%)	193 (1.2%)
Household income ³				
Very low	19422 (19.2%)	2863 (17.7%)	13265 (19.2%)	3294 (20.6%)
Low	22159 (21.9%)	3487 (21.5%)	15137 (21.9%)	3535 (22.1%)
Medium	22634 (22.3%)	3831 (23.6%)	15417 (22.3%)	3386 (21.2%)
High	17767 (17.5%)	3095 (19.1%)	12027 (17.4%)	2645 (16.5%)
Very high	4725 (4.7%)	819 (5.1%)	3188 (4.6%)	718 (4.5%)
Missing ¹	14652 (14.5%)	2109 (13.0%)	10132 (14.6%)	2411 (15.1%)
Cohabitation				
With partner	73896 (72.9%)	12054 (74.4%)	50748 (73.4%)	11094 (69.4%)
Single	8341 (8.2%)	1418 (8.8%)	5467 (7.9%)	1456 (9.1%)
Missing ¹	19122 (18.9%)	2732 (16.9%)	12951 (18.7%)	3439 (21.5%)

Smoking status				
Never	55643 (54.9%)	9149 (56.5%)	37876 (54.8%)	8618 (53.9%)
Former	34805 (34.3%)	5342 (33.0%)	23838 (34.5%)	5625 (35.2%)
Current	10416 (10.3%)	1634 (10.1%)	7119 (10.3%)	1663 (10.4%)
Missing ¹	495 (0.5%)	79 (0.5%)	333 (0.5%)	83 (0.5%)
Menopause ⁴				
No	12986 (12.8%)	2887 (17.8%)	8096 (11.7%)	2003 (12.5%)
Yes	32745 (32.3%)	4046 (25.0%)	23034 (33.3%)	5665 (35.4%)
Missing ¹	55628 (54.9%)	9271 (57.2%)	38036 (55.0%)	8321 (52.0%)
Morbidity count				
None	23788 (23.5%)	4459 (27.5%)	16311 (23.6%)	3018 (18.9%)
One	26923 (26.6%)	4581 (28.3%)	18615 (26.9%)	3727 (23.3%)
Two	20535 (20.3%)	3195 (19.7%)	14011 (20.3%)	3329 (20.8%)
Three	13157 (13.0%)	1857 (11.5%)	9001 (13.0%)	2299 (14.4%)
Four	7553 (7.5%)	989 (6.1%)	5077 (7.3%)	1487 (9.3%)
Five+	9387 (9.3%)	1119 (6.9%)	6141 (8.9%)	2127 (13.3%)
Missing ¹	16 (0.0%)	4 (0.0%)	10 (0.0%)	2 (0.0%)
Fasting time ⁵ ; mean (SD)	3.75 (2.40)	3.74 (2.47)	3.74 (2.39)	3.79 (2.38)
Body mass index ⁶ ; mean (SD)	27.43 (4.73)	26.17 (4.07)	27.41 (4.57)	28.80 (5.59)

Note: GCSEs = general certificate of secondary education; CSE = certificate of secondary education; NVQ = national vocational qualification; HND = higher national diploma; HNC = higher national certificate. MileAge delta (adj.) derived from the Cubist rule-based regression model. ¹Missing data may also include “do not know”, “prefer not to answer”, “not applicable” or related responses. ²Also includes ‘other professional qualifications’. ³Annual household income groups: very low (<£18,000), low (£18,000–£30,999), middle (£31,000–£51,999), high (£52,000–£100,000) and very high (>£100,000). ⁴*n* = 59519 females. ⁵*n* = 3 missing. ⁶*n* = 345 missing.

325

326 **Metabolite-wide associations**

327 165/168 metabolites were associated with chronological age ($p < 0.05/168$). While most
 328 metabolite levels were elevated in older individuals (e.g., Omega 3, citrate and glucose),
 329 seven, including albumin, glycine and histidine, were negatively associated with
 330 chronological age (**Figure S34; Additional file 1**). Amongst the 119 metabolites associated
 331 with all-cause mortality, GlycA was most strongly associated with a higher mortality hazard
 332 (HR = 1.22, 95% CI 1.20-1.25, $p < 0.001$), whereas the degree of unsaturation,
 333 docosahexaenoic acid (DHA) and Omega 3 were strongly associated with a lower mortality
 334 hazard (**Figure S35; Additional file 2**). Notably, 116 metabolites associated with
 335 chronological age also predicted mortality, with GlycA, Omega 3 and DHA amongst the
 336 most strongly associated metabolites of both age and mortality (**Figure 1d**). Between 87%
 337 and 95% of the metabolites that were statistically significantly associated with other health
 338 indicators (e.g., frailty and health status) were associated with chronological age (**Figure**
 339 **S36**). The exception was telomere length for which only 53% of statistically significant
 340 metabolites were shared with chronological age.

341

342 **Predictive model performance**

343 Predictive performance estimates in the 90% training ($n = 91,222$ to $91,226$) and 10% test
344 sets are shown in [Table S3](#). The nested cross-validation mean absolute error (MAE) in the
345 test sets ($n = 10,133$ to $10,137$) ranged from 5.31 to 6.36 years, with the support vector
346 regression with a radial basis function (SVM radial) performing best and the MARS
347 ensemble performing worst. The root-mean-square error (RMSE) ranged from 6.60 to 7.58
348 years. Correlation coefficients between predicted and chronological age ranged from 0.36 to
349 0.59, with R^2 values between 0.13 and 0.35. The difference in predictive performance
350 between the training and test sets, i.e., the model's optimism which may indicate poor
351 generalization to unseen data, was generally low (e.g., $MAE_{\text{difference}} < 0.15$ for 10/17 models).
352 However, certain tree-based models (bagging, random forest and XGBoost) and the k -nearest
353 neighbors model overfit the training data ($MAE_{\text{difference}} = -1.51$ to -5.83), with correlation
354 coefficients between predicted and chronological age of $r > 0.8$ in the training sets ([Figure](#)
355 [S40](#)). [Figure 2a](#) shows the nested cross-validation MAEs for all models. For comparison,
356 drawing random samples from a uniform distribution between the sample's minimum and
357 maximum chronological age, i.e., a random prediction model, resulted in a $MAE = 9.79$.
358 Predicting the sample mean, i.e., a null model, resulted in a $MAE = 6.96$. Additional plots
359 showing other performance measures (MAE, RMSE, r and R^2) in the training and test sets are
360 presented in the supplement ([Figures S37-S43](#)). There were moderate to high correlations
361 between the predicted age values of the various models ($r = 0.48$ to > 0.99) ([Figure 2b](#)). High
362 correlations ($r > 0.87$) amongst the most accurate models suggest they capture similar
363 patterns in the data. Omega 3, albumin and citrate were amongst the most important
364 contributors to predictive accuracy ([Figure S44](#)).

365

366 **Age bias correction**

367 All models overestimated the age of young individuals and underestimated the age of older
368 individuals ([Figure S44](#)). Applying a statistical correction (see Methods) to the predicted age
369 values removed this bias ([Figures 2c-e](#) and [S45](#)). The predicted age values were originally
370 within the chronological age range (39 to 70 years) of the sample for most individuals.
371 Across *all* models, 0.23% ($n = 238$) and 0.96% ($n = 976$) of predictions were below or above
372 the minimum and maximum age, respectively ([Table S4](#)). More predicted age values were
373 outside the chronological age range (up to 8.27%, $n = 8382$ for a single model) after the age
374 bias correction. Re-calculating the predictive performance estimates after the age bias

375 correction suggested higher accuracy (MAE = 2.12 to 3.40; **Figure 2f**). The overall
376 performance rankings across the models inverted, with the models that originally predicted
377 chronological age best showing reduced accuracy (**Figures S46-S48**). The age bias adjusted
378 MileAge delta ranged from -18.94 years younger to 16.05 years older for the Cubist rule-
379 based regression model, with 15.99% ($n = 16,204$) and 15.77% ($n = 15,989$) of the sample
380 having a MileAge delta (adj.) of at least 3.75 years below or above the mean (**Figure 2g**;
381 **Table S5**).

382

383 **Associations with health indicators**

384 Descriptive statistics for the health indicators are shown in **Table S6**. Having an older
385 predicted than chronological age was associated with higher frailty index scores across all
386 models (**Table S7**). This extended to the frailty phenotype for all models when comparing
387 individuals with a MileAge delta (adj.) more than one standard deviation above and below
388 the mean, and for 12/17 models when comparing the middle of the distribution to individuals
389 with MileAge delta (adj.) values more than one standard deviation below the mean (**Table**
390 **S8**). For telomere length, we observed a group difference for 12/17 models when comparing
391 the tails of the distribution, and for 9/17 models when comparing the middle of the
392 distribution to the reference group (**Table S9**). Having an older predicted than chronological
393 age was generally associated with chronic illness and poor self-rated health (**Tables S10-**
394 **S12**). An exception to this pattern were the MARS models, for which an older predicted than
395 chronological age was associated with *longer* telomeres, and for which there was little
396 evidence of statistically significant differences in health between individuals with MileAge
397 delta (adj.) values in the middle of the distribution and the reference group.

398

399 MileAge delta (adj.) derived from the Cubist rule-based regression model was most strongly
400 associated with most health indicators (**Figure 3a**). Individuals with a MileAge delta (adj.)
401 greater than one standard deviation above the mean had higher frailty index scores than
402 individuals with a MileAge delta (adj.) smaller than one standard deviation below the mean
403 ($\beta = 0.023$, 95% CI 0.021–0.024, $p < 0.001$). This group difference was approximately
404 equivalent to an 18.3-year chronological age difference in frailty index scores ($\beta = 0.023$
405 divided by $\beta = 0.001255$ derived from a linear model, $y_{\text{frailty index}} \sim X_{\text{chronological age}}$).
406 Individuals with an older predicted than chronological age were also more likely to be
407 physically frail (OR = 1.29, 95% CI 1.23–1.35, $p < 0.001$) and had shorter telomeres ($\beta =$
408 0.052, 95% CI 0.030 to 0.073, $p < 0.001$) equivalent to a 2.2-year chronological age

409 difference in telomere length. Such individuals were also more likely to have a long-standing
410 illness (OR = 1.82, 95% CI 1.73–1.91, $p < 0.001$), poorer health status (OR = 1.85, 95% CI
411 1.76–1.94, $p < 0.001$) and worse self-rated health (OR = 1.72, 95% CI 1.65–1.80, $p < 0.001$).
412 Generalised additive models showed that positive MileAge delta (adj.) values, indicating
413 accelerated biological ageing, were robustly associated with unfavourable health (Figure 3b),
414 whereas negative MileAge delta (adj.) values were only weakly associated with favourable
415 health, a pattern that was consistent across most models (Figures S49-S54).

416

417 **Predicting mortality**

418 The median duration of follow-up of censored individuals was 13.87 years (IQR = 1.37
419 years), with 1,361,970 person-years of follow-up. There were 8113 deaths amongst 101,274
420 participants ($n = 85$ missing). MileAge (adj.) was strongly associated with all-cause
421 mortality, comparable to chronological age (Figures 4a-e). In the prospective analyses we
422 examined the age bias adjusted MileAge delta and models were adjusted for chronological
423 age and sex, with age (in years) as the underlying time axis (Figure S55 and Table S13).

424

425 For the Cubist rule-based regression model, the hazard ratio (HR) comparing individuals with
426 a MileAge delta (adj.) greater than one standard deviation above and below the mean was HR
427 = 1.52 (95% CI 1.41-1.64, $p < 0.001$). Individuals with a MileAge delta (adj.) between one
428 standard deviation above and below the mean had a statistically significantly higher mortality
429 risk for 14/17 models (p between 0.03 and < 0.001) (Table S14). Comparing the bottom and
430 top 10% of the MileAge delta (adj.) distribution, instead of one standard deviation above and
431 below the mean, resulted in greater differences (e.g., HR = 1.63, 95% CI 1.48-1.79, $p < 0.001$
432 for the Cubist model). Individuals in between the tails of the distribution had a higher
433 mortality risk compared to the bottom 10% for 14/17 models (Figure S56 and Table S15).

434 When comparing individuals with a positive and negative MileAge delta (adj.), we found that
435 individuals with an older predicted than chronological age had a higher mortality risk for all
436 models except the MARS models (Figure S57 and Table S16). Modelling the mortality
437 hazard as a spline function of MileAge delta (adj.) suggested that positive values were
438 strongly associated with a higher mortality hazard, while there was little evidence that
439 negative values were associated with a lower mortality hazard (Figure S58).

440

441 Females had slightly higher MileAge delta (adj.) values than males (Figure 4f), a pattern
442 which we observed across all models (Figure S59). The mortality hazard of individuals with a

443 MileAge delta (adj.) greater than one standard deviation above the mean was elevated in both
444 females (HR = 1.26, 95% CI 1.11-1.43, $p < 0.001$) and males (HR = 1.73, 95% CI 1.57-1.91,
445 $p < 0.001$) (Figures S60-S61; Table S17). The difference in mortality between individuals
446 with a MileAge delta (adj.) in the middle of the distribution and the reference group was only
447 statistically significant in males (HR = 1.14, 95% CI 1.05-1.23, $p = 0.002$). Stratifying the
448 sample by self-rated health, the mortality hazard of individuals with a MileAge delta (adj.)
449 greater than one standard deviation above the mean was higher in all strata (e.g., HR = 1.41,
450 95% CI 1.11-1.78, $p < 0.001$ for poor self-rated health) except for individuals with excellent
451 health (Figure 4g and Table S17). The mortality hazard of individuals with a MileAge delta
452 (adj.) greater than one standard deviation above the mean was higher in the age groups above
453 50 years (Figures S62 and 4h; Table S17).

454

455 **Comparison with other ageing markers**

456 A comparison of the all-cause mortality hazard associated with MileAge delta (adj.) and
457 other ageing marker subgroups defined by the standard deviation from the mean showed that
458 the largest hazard ratio (HR = 2.90) was observed for the frailty index (Figure 5a). The
459 smallest hazard ratio was observed for telomere length (HR = 1.31) (Table S18), with
460 MileAge delta (adj.) (HR = 1.52) and grip strength (HR = 1.90) in-between. Adding each
461 ageing marker individually as a continuous variable to a base model that included
462 chronological age and sex improved prediction of all-cause mortality, with the best prediction
463 observed for the frailty index (C-index 0.737, 95% CI 0.732 to 0.742 vs C-index 0.716, 95%
464 CI 0.711 to 0.722 for the base model) (Figure 5b and Table S19). Modelling the mortality
465 hazard as a spline function of the ageing markers, to identify potential non-linear effects,
466 suggested that the all-cause mortality hazard was considerably higher in individuals with an
467 older predicted than chronological age. For example, compared to the sample median
468 MileAge delta (adj.), which was equivalent to no difference between predicted and
469 chronological age, a MileAge delta (adj.) of 10 was associated with a HR of about 2.7, i.e., a
470 170% higher mortality hazard (Figure 5c).

471 Discussion

472 In 101,359 UK Biobank participants with Nightingale Health metabolomics data, we
473 observed that most metabolite levels varied by chronological age, with considerable evidence
474 of non-linear associations. Across the machine learning algorithms employed to develop
475 ageing clocks from circulating plasma metabolites, the nested cross-validation mean absolute
476 error between predicted age (MileAge) and chronological age ranged from 5.31 to 6.36 years
477 (R^2 between 0.13 and 0.35). All models overestimated age in young individuals and
478 underestimated age in older individuals. After applying a statistical correction to remove this
479 age bias, 31.76% of participants had adjusted MileAge delta values of at least 3.75 years,
480 highlighting the potential of metabolomic ageing clocks to differentiate between individuals
481 of the same chronological age (Hertel et al., 2019). While there was a high degree of
482 consistency across the top performing models such as support vector regression, tree-based
483 and rule-based ensembles, the ageing clock derived from a Cubist rule-based regression
484 model (MAE = 5.42) was most strongly associated with most health indicators. We observed
485 across most models that individuals with an older predicted than chronological age,
486 indicating accelerated biological ageing, were frailer, had shorter telomeres, were more likely
487 to have a chronic illness, rated their health worse and had a higher mortality risk.

488

489 Multiple studies have developed biological ageing clocks trained on chronological age from
490 metabolomics data. The seminal study by Menni et al. (2013) derived a metabolite age score
491 as a linear combination of 22 plasma metabolites that were correlated with chronological age
492 in 6055 twins, achieving an R^2 of 59% and a hazard ratio for all-cause mortality of HR = 1.08
493 per year. Hertel et al. (2016) tested a multivariable linear regression and a fractional
494 polynomial model in 3611 participants, with the latter achieving a correlation between
495 predicted and chronological age of $r = 0.53$ (RMSE = 11.19) in men and $r = 0.61$ (RMSE =
496 10.37) in women. Their metabolomic ageing clock included 59 urinary metabolites and was
497 predictive of all-cause mortality (HR = 1.24 per SD). Robinson et al. (2020) developed
498 several ageing clocks using elastic net models in 2238 participants, with correlations between
499 predicted and chronological age of $r = 0.45$ (MAE = 4.17) to $r = 0.83$ (MAE = 6.49). Akker
500 et al. (2020) developed an ageing clock, MetaboAge, from 56 metabolites in 18,716
501 participants from 24 community and hospital-based cohorts using a linear regression model,
502 achieving a correlation of $r = 0.65$ and a median absolute error of 7.3. An independent
503 external validation of this clock observed a notably lower correlation of $r = 0.21$ (Macdonald-

504 Dunlop et al., 2022). The same study also developed a clock from NMR metabolomics data
505 (81/86 metabolites selected) in 1643 individuals, which achieved a correlation of $r = 0.74$ but
506 failed to replicate in a validation cohort, and another clock from mass spectrometry
507 metabolomics (181/682 metabolites selected) in 861 individuals, which achieved a
508 correlation of $r = 0.81$ (Macdonald-Dunlop et al., 2022). An updated ageing clock,
509 MetaboAge 2.0, in the BBMRI-nl data that included 65 metabolites achieved an R^2 of 0.451
510 and 0.449 for a linear regression and elastic net model, respectively (Bizzarri et al., 2023).

511

512 Metabolomic ageing clocks trained on chronological age are generally less accurate than
513 ageing clocks derived from other types of omics data (Rutledge et al., 2022). Nevertheless,
514 our most predictive model (MAE = 5.31 years) had a similar accuracy as a deep learning
515 ageing clock (MAE = 5.68) derived from blood markers, biometrics and sex in the China
516 Health and Retirement Longitudinal Study. An elastic net model in the same data achieved a
517 MAE = 6.19 years (Galkin et al., 2022), while the elastic net model in our study had a lower
518 MAE = 5.70, likely due to the larger sample size. While a discussion of how well different
519 ageing clocks predict health outcomes is beyond the scope of this study, the most widely
520 tested epigenetic ageing clocks that were trained on chronological age are weak predictors of
521 mortality (B. H. Chen et al., 2016; Fransquet, Wrigglesworth, Woods, Ernst, & Ryan, 2019).
522 Second-generation ageing clocks are more predictive of mortality. For example, a one-year
523 increase in PhenoAge, which was trained on physiological dysregulation, was associated with
524 a 9% increase in mortality risk. Its epigenetic derivation, DNAm PhenoAge, was associated
525 with a 4.5% increase in all-cause mortality (Levine et al., 2018). GrimAge, another popular
526 mortality risk predictor that incorporates chronological age, sex and eight DNA methylation
527 surrogate markers (seven for plasma proteins and one for smoking pack-years) strongly
528 predicts mortality and age-related diseases (Lu et al., 2019). A recent clock developed from
529 circulating biomarkers and trained to predict mortality in the UK Biobank ($n = 307,000$)
530 using an elastic net Cox model (Bortz et al., 2023) yielded a 9.2% relative increase in
531 prediction compared to the PhenoAge model. However, the improvement in prediction over a
532 model that included chronological age and sex was modest (C-index 0.715 vs 0.762,
533 compared to 0.716 vs 0.719 in our study; though note that our clock was not trained to predict
534 mortality). These findings suggest that certain omics clocks capture physiologically relevant
535 signals more, while first-generation epigenetic clocks are specifically good at predicting
536 chronological time (Rutledge et al., 2022).

537

538 Although chronological age prediction is valuable in fields such as forensics (Vidaki et al.,
539 2017), it is of limited use in population health and geroscience, given that chronological age
540 is non-modifiable (Robinson & Lau, 2020). A perfect prediction model would merely tell us
541 about chronological, not biological, age (Nakamura et al., 1988). It is the *difference* between
542 predicted and chronological age (MileAge delta) that serves as an indicator of accelerated or
543 decelerated ageing. A less accurate chronological age prediction does not necessarily indicate
544 a worse biological age model (Hertel et al., 2019), hence we also tested algorithms that were
545 expected to perform less well at predicting chronological age (e.g., bagging). Prior studies
546 suggested that biological age estimates derived from physical activity (Pyrkov et al., 2018) or
547 epigenetic data (Zhang et al., 2019) with higher predictive accuracy of chronological age
548 were less predictive of all-cause mortality. Our study showed that the models that were most
549 predictive of chronological age were generally also more strongly associated with health and
550 mortality, though we note that the pattern of predictive accuracy largely inverted after we
551 applied the age bias correction.

552

553 We report several additional analyses, including variable importance scores and
554 benchmarking against other ageing markers, for the ageing clock derived from the Cubist
555 rule-based regression model, which was most strongly associated with most health indicators.
556 There are, however, several conclusions that can be drawn across most of the machine
557 learning algorithms tested. First, the wide range of the MileAge delta values quantifies the
558 latent patterns in the metabolomics data not captured by chronological age and suggests that
559 our ageing clocks approximate (past) rate of biological ageing for people of the same
560 chronological age. Second, the associations between most ageing clocks, health and mortality
561 demonstrate that these clocks capture biologically relevant information, which may find
562 applications in health tracking, nutrition or in clinical trials (e.g., sample stratification). A key
563 finding across most ageing clock models tested here was that associations with health and
564 mortality were stronger in individuals with an older predicted than chronological age and less
565 so in individuals with a younger predicted than chronological age.

566

567 Several of the algorithms included in our comparison, including those that were most
568 predictive of chronological age, mortality and health, allowed for non-linear relationships in
569 the data, which were often not considered in previous studies (Panyard et al., 2022). A recent
570 review found that most molecular ageing clocks were developed using linear models with
571 regularization, whereas few used non-linear models (Xia, Wang, Yu, Chen, & Han, 2021).

572 Although it has been asserted that age-related physiological markers are linearly associated
573 with age (Pyrkov et al., 2018), we have shown here and in previous studies (Mutz, Hoppen, et
574 al., 2022; Mutz & Lewis, 2021; Mutz, Young, et al., 2022) that this does not apply to many
575 biological markers. To enable comparability between studies, we provide a comprehensive
576 set of statistical estimates and developed our ageing clock using metabolites measured in
577 absolute concentrations instead of relative to other measures. Although it may be argued that
578 quantification of a smaller number of metabolites would in principle be more feasible and
579 convenient in clinical practice, all metabolites included in our model can be quantified from a
580 single assay with minimal sample preparation required (Würtz et al., 2017).

581

582 **Limitations and future directions**

583 Our study had certain limitations. Some algorithms that have previously been used to develop
584 biological ageing clocks, for example deep learning (Zhavoronkov, Li, Ma, & Mamoshina,
585 2019), or approaches combining HSIC LASSO feature selection with non-linear support
586 vector regression (Takahashi et al., 2020) were not tested, and could be explored in future
587 studies. Our ageing clock provides a “systems level” indicator of age-related changes in
588 metabolites; future clocks may be developed at the tissue or cellular level. Plasma samples
589 may differ from other body fluids, e.g., serum, urine or cerebrospinal fluid. The metabolite
590 coverage of the Nightingale Health platform is lipid focussed and mostly covers larger
591 molecules, while there are potentially over 217,000 endogenous and exogenous molecules
592 (Wishart et al., 2021). Nevertheless, this platform enables robust assessment of these
593 metabolites in a single experiment (Würtz et al., 2017). Although more complex ageing
594 clocks could be developed using technologies with wider metabolite coverage, prior analyses
595 suggested that a majority of metabolites associated with age were related to lipid and amino
596 acid pathways, both of which were included here (Menni et al., 2013). As in previous studies,
597 we observed a systematic overestimation of age in young individuals and underestimation of
598 age in older individuals (Nakamura et al., 1988). This bias is neither data nor method specific
599 and may be explained by regression to the mean (Liang, Zhang, & Niu, 2019) of the training
600 data (Jones, Lee, & Topol, 2022). To account for this bias, we have adjusted the predicted
601 age and included chronological age as a covariate in the health association analyses (Xia et
602 al., 2021). Longitudinal ageing metrics may be more robustly associated with certain health
603 outcomes than cross-sectional ageing metrics, e.g., with physical and cognitive decline but
604 not, for example, multimorbidity (Kuo et al., 2022). Future research should develop

605 metabolomic ageing clocks from longitudinal data. Finally, the lack of independent data for
606 external validation is a limitation.

607

608 **Conclusions**

609 Metabolomic ageing clocks derived from multiple machine learning algorithms were robustly
610 associated with health indicators and mortality. We found that our ageing clock (MileAge)
611 derived from a Cubist rule-based regression model was overall most strongly associated with
612 health indicators. Individuals with MileAge values greater than their chronological age,
613 indicating accelerated biological ageing, were frailer, had shorter telomeres, were more likely
614 to have a chronic illness, rated their health worse and had a higher mortality risk.

615 Metabolomic ageing clocks hold significant promise for research on lifespan and healthspan
616 extension, as they provide a proxy of biological ageing that is potentially modifiable. These
617 clocks may also help identify health risks before clinical symptoms emerge. As such,
618 biological ageing clocks may contribute to health risk assessments, complementing clinical
619 biomarkers. However, the utility of ageing clocks is not limited to risk stratification, but also
620 in providing an intuitive, year-based metric for health tracking that may help individuals
621 proactively engage with their health.

622 **Acknowledgments**

623 This research is funded by the National Institute for Health and Care Research (NIHR)
624 Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation
625 Trust and King's College London. The views expressed are those of the authors and not
626 necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
627 Computational analyses were supported by: King's College London. (2023). King's
628 Computational Research, Engineering and Technology Environment (CREATE). Retrieved
629 May 24, 2023, from <https://doi.org/10.18742/rnvf-m076>. This research has been conducted
630 using data from UK Biobank, a major biomedical database. Data access permission has been
631 granted under UK Biobank application 45514.

632

633 **Financial disclosures**

634 CML is a member of the scientific advisory board of Myriad Neuroscience, has received
635 speaker fees from SYNLAB and received consultancy fees from UCB. JM and RI declare no
636 financial conflict of interest.

637

638 **Authorship contributions**

639 JM conceived the idea of the study, acquired the data, carried out the analysis, interpreted the
640 findings and wrote the manuscript. CML and RI interpreted the findings and reviewed the
641 manuscript. All authors read and approved the final manuscript.

642

643 **Ethics**

644 Ethical approval for the UK Biobank study has been granted by the National Information
645 Governance Board for Health and Social Care and the NHS North West Multicentre Research
646 Ethics Committee (11/NW/0382). No project-specific ethical approval is needed.

647

648 **Data sharing statement**

649 The data used are available to all *bona fide* researchers for health-related research that is in
650 the public interest, subject to an application process and approval criteria. Study materials are
651 publicly available online at <http://www.ukbiobank.ac.uk>.

652

653 **Supplementary material**

654 Supplementary information is available online.

655 **References**

656

657 Akker, E. B. v. d., Trompet, S., Wolf, J. J. H. B., Beekman, M., Suchiman, H. E. D., Deelen,
658 J., . . . Slagboom, P. E. (2020). Metabolic Age Based on the BBMRI-NL 1H-NMR
659 Metabolomics Repository as Biomarker of Age-related Disease. *Circulation:
660 Genomic and Precision Medicine*, 13(5), 541-547.

661 doi:doi:10.1161/CIRCGEN.119.002610

662 Bates, S., Hastie, T., & Tibshirani, R. Cross-Validation: What Does It Estimate and How
663 Well Does It Do It? *Journal of the American Statistical Association*, 1-12.

664 doi:10.1080/01621459.2023.2197686

665 Bizzarri, D., Reinders, M. J. T., Beekman, M., BBMRI-NL, Slagboom, P. E., & Akker, E. B.
666 v. d. (2023). Technical report: A comprehensive comparison between different
667 quantification versions of Nightingale Health's 1H-NMR metabolomics platform.

668 *medRxiv*, 2023.2007.2003.23292168. doi:10.1101/2023.07.03.23292168

669 Bortz, J., Guariglia, A., Klaric, L., Tang, D., Ward, P., Geer, M., . . . Joshi, P. K. (2023).

670 Biological Age Estimation Using Circulating Blood Biomarkers. *medRxiv*,

671 2023.2002.2023.23285864. doi:10.1101/2023.02.23.23285864

672 Boser, B. E., Guyon, I. M., & Vapnik, V. N. (1992). *A training algorithm for optimal margin
673 classifiers*. Paper presented at the Proceedings of the fifth annual workshop on

674 Computational learning theory, Pittsburgh, Pennsylvania, USA.

675 <https://doi.org/10.1145/130385.130401>

676 Breiman, L. (1996). Bagging predictors. *Machine Learning*, 24(2), 123-140.

677 doi:10.1007/BF00058655

678 Breiman, L. (2001). Random Forests. *Machine Learning*, 45(1), 5-32.

679 doi:10.1023/A:1010933404324

680 Breiman, L., Friedman, J., Olshen, R., & Stone, C. (1984). Classification and Regression
681 Trees.

682 Buergel, T., Steinfeldt, J., Ruyoga, G., Pietzner, M., Bizzarri, D., Vojinovic, D., . . .

683 Landmesser, U. (2022). Metabolomic profiles predict individual multidisease

684 outcomes. *Nature Medicine*, 28(11), 2309-2320. doi:10.1038/s41591-022-01980-3

685 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., . . . O'Connell, J.

686 (2018). The UK Biobank resource with deep phenotyping and genomic data. *Nature*,

687 562(7726), 203-209. doi:<https://doi.org/10.1038/s41586-018-0579-z>

- 688 Chen, B. H., Marioni, R. E., Colicino, E., Peters, M. J., Ward-Caviness, C. K., Tsai, P. C., . . .
689 Horvath, S. (2016). DNA methylation-based measures of biological age: meta-
690 analysis predicting time to death. *Aging (Albany NY)*, 8(9), 1844-1865.
691 doi:10.18632/aging.101020
- 692 Chen, T., & Guestrin, C. (2016). *XGBoost: A Scalable Tree Boosting System*. Paper presented
693 at the Proceedings of the 22nd ACM SIGKDD International Conference on
694 Knowledge Discovery and Data Mining, San Francisco, California, USA.
695 <https://doi.org/10.1145/2939672.2939785>
- 696 Chipman, H. A., George, E. I., & McCulloch, R. E. (2010). BART: Bayesian additive
697 regression trees. *The Annals of Applied Statistics*, 4(1), 266-298, 233. Retrieved from
698 <https://doi.org/10.1214/09-AOAS285>
- 699 Cole, J. H., & Franke, K. (2017). Predicting Age Using Neuroimaging: Innovative Brain
700 Ageing Biomarkers. *Trends in Neurosciences*, 40(12), 681-690.
701 doi:<https://doi.org/10.1016/j.tins.2017.10.001>
- 702 Cover, T., & Hart, P. (1967). Nearest neighbor pattern classification. *IEEE Transactions on*
703 *Information Theory*, 13(1), 21-27. doi:10.1109/TIT.1967.1053964
- 704 Cox, D. R. (1972). Regression models and life tables. *Journal of the Royal Statistical*
705 *Society: Series B (Methodological)*, 34(2), 187-202.
- 706 de Lange, A. G., & Cole, J. H. (2020). Commentary: Correction procedures in brain-age
707 prediction. *Neuroimage Clin*, 26, 102229. doi:10.1016/j.nicl.2020.102229
- 708 Deelen, J., Kettunen, J., Fischer, K., van der Spek, A., Trompet, S., Kastenmüller, G., . . .
709 Slagboom, P. E. (2019). A metabolic profile of all-cause mortality risk identified in an
710 observational study of 44,168 individuals. *Nature Communications*, 10(1), 3346.
711 doi:10.1038/s41467-019-11311-9
- 712 Drucker, H., Burges, C. J., Kaufman, L., Smola, A., & Vapnik, V. (1996). Support Vector
713 Regression Machines. *Advances in neural information processing systems*, 9.
- 714 Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018). Inflammaging: a
715 new immune–metabolic viewpoint for age-related diseases. *Nature Reviews*
716 *Endocrinology*, 14(10), 576-590. doi:10.1038/s41574-018-0059-4
- 717 Fransquet, P. D., Wrigglesworth, J., Woods, R. L., Ernst, M. E., & Ryan, J. (2019). The
718 epigenetic clock as a predictor of disease and mortality risk: a systematic review and
719 meta-analysis. *Clinical Epigenetics*, 11(1), 62. doi:10.1186/s13148-019-0656-7
- 720 Friedman, J., H. (1991). Multivariate Adaptive Regression Splines. *The Annals of Statistics*,
721 19(1), 1-67. doi:10.1214/aos/1176347963

- 722 Friedman, J. H., & Popescu, B. E. (2008). Predictive learning via rule ensembles. *The Annals*
723 *of Applied Statistics*, 916-954.
- 724 Galkin, F., Kochetov, K., Koldasbayeva, D., Faria, M., Fung, H. H., Chen, A. X., &
725 Zhavoronkov, A. (2022). Psychological factors substantially contribute to biological
726 aging: evidence from the aging rate in Chinese older adults. *Aging (Albany NY)*,
727 *14*(18), 7206-7222. doi:10.18632/aging.204264
- 728 Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sadda, S., . . . Zhang, K. (2013).
729 Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging
730 Rates. *Molecular Cell*, *49*(2), 359-367.
731 doi:<https://doi.org/10.1016/j.molcel.2012.10.016>
- 732 Hertel, J., Frenzel, S., König, J., Wittfeld, K., Fuellen, G., Holtfreter, B., . . . Grabe, H. J.
733 (2019). The informative error: A framework for the construction of individualized
734 phenotypes. *Statistical Methods in Medical Research*, *28*(5), 1427-1438.
735 doi:10.1177/0962280218759138
- 736 Hertel, J., Friedrich, N., Wittfeld, K., Pietzner, M., Budde, K., Van der Auwera, S., . . .
737 Grabe, H. J. (2016). Measuring Biological Age via Metabonomics: The Metabolic
738 Age Score. *Journal of Proteome Research*, *15*(2), 400-410.
739 doi:10.1021/acs.jproteome.5b00561
- 740 Hoerl, A. E., & Kennard, R. W. (1970). Ridge Regression: Biased Estimation for
741 Nonorthogonal Problems. *Technometrics*, *12*(1), 55-67.
742 doi:10.1080/00401706.1970.10488634
- 743 Hoogendijk, E. O., Afilalo, J., Ensrud, K. E., Kowal, P., Onder, G., & Fried, L. P. (2019).
744 Frailty: implications for clinical practice and public health. *The Lancet*, *394*(10206),
745 1365-1375. doi:[https://doi.org/10.1016/S0140-6736\(19\)31786-6](https://doi.org/10.1016/S0140-6736(19)31786-6)
- 746 Horvath, S., & Raj, K. (2018). DNA methylation-based biomarkers and the epigenetic clock
747 theory of ageing. *Nature Reviews Genetics*, *19*, 371-384.
748 doi:<https://doi.org/10.1038/s41576-018-0004-3>
- 749 Jones, D. T., Lee, J., & Topol, E. J. (2022). Digitising brain age. *The Lancet*, *400*(10357),
750 988. doi:10.1016/S0140-6736(22)01782-2
- 751 Kaplan, E. L., & Meier, P. (1958). Nonparametric estimation from incomplete observations.
752 *Journal of the American Statistical Association*, *53*(282), 457-481.
- 753 Kuhn, M., & Johnson, K. (2013a). Nonlinear Regression Models. In M. Kuhn & K. Johnson
754 (Eds.), *Applied Predictive Modeling* (pp. 141-171). New York, NY: Springer New
755 York.

- 756 Kuhn, M., & Johnson, K. (2013b). Regression Trees and Rule-Based Models. In M. Kuhn &
757 K. Johnson (Eds.), *Applied Predictive Modeling* (pp. 173-220). New York, NY:
758 Springer New York.
- 759 Kuo, P.-L., Schrack, J. A., Levine, M. E., Shardell, M. D., Simonsick, E. M., Chia, C. W., . . .
760 Ferrucci, L. (2022). Longitudinal phenotypic aging metrics in the Baltimore
761 Longitudinal Study of Aging. *Nature Aging*, *2*(7), 635-643. doi:10.1038/s43587-022-
762 00243-7
- 763 Lai, T.-P., Wright, W. E., & Shay, J. W. (2018). Comparison of telomere length measurement
764 methods. *Philosophical Transactions of the Royal Society B: Biological Sciences*,
765 *373*(1741), 20160451.
- 766 Lawton, K. A., Berger, A., Mitchell, M., Milgram, K. E., Evans, A. M., Guo, L., . . . Milburn,
767 M. V. (2008). Analysis of the adult human plasma metabolome. *Pharmacogenomics*,
768 *9*(4), 383-397. doi:10.2217/14622416.9.4.383
- 769 Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., . . . Horvath,
770 S. (2018). An epigenetic biomarker of aging for lifespan and healthspan. *Aging*
771 (*Albany NY*), *10*(4), 573-591. doi:10.18632/aging.101414
- 772 Liang, H., Zhang, F., & Niu, X. (2019). Investigating systematic bias in brain age estimation
773 with application to post-traumatic stress disorders. *Human Brain Mapping*, *40*(11),
774 3143-3152. doi:<https://doi.org/10.1002/hbm.24588>
- 775 López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks
776 of aging: An expanding universe. *Cell*, *186*(2), 243-278.
777 doi:10.1016/j.cell.2022.11.001
- 778 Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., . . . Horvath, S. (2019).
779 DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany*
780 *NY)*, *11*(2), 303-327. doi:10.18632/aging.101684
- 781 Macdonald-Dunlop, E., Taba, N., Klarić, L., Frkatović, A., Walker, R., Hayward, C., . . .
782 Joshi, P. K. (2022). A catalogue of omics biological ageing clocks reveals substantial
783 commonality and associations with disease risk. *Aging (Albany NY)*, *14*(2), 623-659.
784 doi:10.18632/aging.203847
- 785 Menni, C., Kastenmüller, G., Petersen, A. K., Bell, J. T., Psatha, M., Tsai, P.-C., . . . Valdes,
786 A. M. (2013). Metabolomic markers reveal novel pathways of ageing and early
787 development in human populations. *International Journal of Epidemiology*, *42*(4),
788 1111-1119. doi:10.1093/ije/dyt094

- 789 Moqri, M., Herzog, C., Poganik, J. R., Justice, J., Belsky, D. W., Higgins-Chen, A., . . .
790 Gladyshev, V. N. (2023). Biomarkers of aging for the identification and evaluation of
791 longevity interventions. *Cell*, *186*(18), 3758-3775. doi:10.1016/j.cell.2023.08.003
- 792 Mutz, J., Choudhury, U., Zhao, J., & Dregan, A. (2022). Frailty in individuals with
793 depression, bipolar disorder and anxiety disorders: longitudinal analyses of all-cause
794 mortality. *medRxiv*, 2022.2002.2023.22271065. doi:10.1101/2022.02.23.22271065
- 795 Mutz, J., Hoppen, T. H., Fabbri, C., & Lewis, C. M. (2022). Anxiety disorders and age-
796 related changes in physiology. *The British Journal of Psychiatry*, 1-10.
797 doi:10.1192/bjp.2021.189
- 798 Mutz, J., & Lewis, C. M. (2021). Lifetime depression and age-related changes in body
799 composition, cardiovascular function, grip strength and lung function: sex-specific
800 analyses in the UK Biobank. *Aging*, *13*(13), 17038-17079.
- 801 Mutz, J., & Lewis, C. M. (2022). Cross-classification between self-rated health and health
802 status: longitudinal analyses of all-cause mortality and leading causes of death in the
803 UK. *Scientific Reports*, *12*(1), 459. doi:<https://doi.org/10.1038/s41598-021-04016-x>
- 804 Mutz, J., Roscoe, C. J., & Lewis, C. M. (2021). Exploring health in the UK Biobank:
805 associations with sociodemographic characteristics, psychosocial factors, lifestyle and
806 environmental exposures. *BMC Medicine*, *19*(1), 240. doi:10.1186/s12916-021-
807 02097-z
- 808 Mutz, J., Young, A. H., & Lewis, C. M. (2022). Age-related changes in physiology in
809 individuals with bipolar disorder. *Journal of Affective Disorders*, *296*, 157-168.
810 doi:<https://doi.org/10.1016/j.jad.2021.09.027>
- 811 Nakamura, E., Miyao, K., & Ozeki, T. (1988). Assessment of biological age by principal
812 component analysis. *Mechanisms of Ageing and Development*, *46*(1), 1-18.
813 doi:[https://doi.org/10.1016/0047-6374\(88\)90109-1](https://doi.org/10.1016/0047-6374(88)90109-1)
- 814 Panyard, D. J., Yu, B., & Snyder, M. P. (2022). The metabolomics of human aging:
815 Advances, challenges, and opportunities. *Science Advances*, *8*(42), eadd6155.
816 doi:doi:10.1126/sciadv.add6155
- 817 Pyrkov, T. V., Slipensky, K., Barg, M., Kondrashin, A., Zhurov, B., Zenin, A., . . . Fedichev,
818 P. O. (2018). Extracting biological age from biomedical data via deep learning: too
819 much of a good thing? *Scientific Reports*, *8*(1), 5210. doi:10.1038/s41598-018-23534-
820 9
- 821 Quinlan, J. R. (1992). *Learning with continuous classes*. Paper presented at the 5th Australian
822 joint conference on artificial intelligence.

- 823 Robinson, O., Chadeau Hyam, M., Karaman, I., Climaco Pinto, R., Ala-Korpela, M.,
824 Handakas, E., . . . Vineis, P. (2020). Determinants of accelerated metabolomic and
825 epigenetic aging in a UK cohort. *Aging Cell*, 19(6), e13149.
826 doi:<https://doi.org/10.1111/ace1.13149>
- 827 Robinson, O., & Lau, C. E. (2020). Measuring biological age using metabolomics. *Aging*
828 (*Albany NY*), 12(22), 22352-22353. doi:10.18632/aging.104216
- 829 Rutledge, J., Oh, H., & Wyss-Coray, T. (2022). Measuring biological age using omics data.
830 *Nature Reviews Genetics*. doi:10.1038/s41576-022-00511-7
- 831 Soininen, P., Kangas, A. J., Würtz, P., Suna, T., & Ala-Korpela, M. (2015). Quantitative
832 Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology
833 and Genetics. *Circulation: Cardiovascular Genetics*, 8(1), 192-206.
834 doi:doi:10.1161/CIRCGENETICS.114.000216
- 835 Solovev, I., Shaposhnikov, M., & Moskalev, A. (2020). Multi-omics approaches to human
836 biological age estimation. *Mechanisms of Ageing and Development*, 185, 111192.
837 doi:<https://doi.org/10.1016/j.mad.2019.111192>
- 838 Takahashi, Y., Ueki, M., Yamada, M., Tamiya, G., Motoike, I. N., Saigusa, D., . . . Tomita,
839 H. (2020). Improved metabolomic data-based prediction of depressive symptoms
840 using nonlinear machine learning with feature selection. *Translational Psychiatry*,
841 10(1), 157. doi:10.1038/s41398-020-0831-9
- 842 Tibshirani, R. (1996). Regression Shrinkage and Selection Via the Lasso. *Journal of the*
843 *Royal Statistical Society: Series B (Methodological)*, 58(1), 267-288.
844 doi:<https://doi.org/10.1111/j.2517-6161.1996.tb02080.x>
- 845 Vidaki, A., Ballard, D., Aliferi, A., Miller, T. H., Barron, L. P., & Syndercombe Court, D.
846 (2017). DNA methylation-based forensic age prediction using artificial neural
847 networks and next generation sequencing. *Forensic Science International: Genetics*,
848 28, 225-236. doi:10.1016/j.fsigen.2017.02.009
- 849 Wishart, D. S., Guo, A., Oler, E., Wang, F., Anjum, A., Peters, H., . . . Gautam, V. (2021).
850 HMDB 5.0: the Human Metabolome Database for 2022. *Nucleic Acids Research*,
851 50(D1), D622-D631. doi:10.1093/nar/gkab1062
- 852 Wold, S., Sjöström, M., & Eriksson, L. (2001). PLS-regression: a basic tool of chemometrics.
853 *Chemometrics and Intelligent Laboratory Systems*, 58(2), 109-130.
854 doi:[https://doi.org/10.1016/S0169-7439\(01\)00155-1](https://doi.org/10.1016/S0169-7439(01)00155-1)
- 855 Würtz, P., Kangas, A. J., Soininen, P., Lawlor, D. A., Davey Smith, G., & Ala-Korpela, M.
856 (2017). Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-

- 857 Scale Epidemiology: A Primer on -Omic Technologies. *American Journal of*
858 *Epidemiology*, 186(9), 1084-1096. doi:10.1093/aje/kwx016
- 859 Xia, X., Wang, Y., Yu, Z., Chen, J., & Han, J.-D. J. (2021). Assessing the rate of aging to
860 monitor aging itself. *Ageing Research Reviews*, 69, 101350.
861 doi:<https://doi.org/10.1016/j.arr.2021.101350>
- 862 Yu, Z., Zhai, G., Singmann, P., He, Y., Xu, T., Prehn, C., . . . Wang-Sattler, R. (2012).
863 Human serum metabolic profiles are age dependent. *Aging Cell*, 11(6), 960-967.
864 doi:<https://doi.org/10.1111/j.1474-9726.2012.00865.x>
- 865 Zhang, Q., Vallerga, C. L., Walker, R. M., Lin, T., Henders, A. K., Montgomery, G. W., . . .
866 Visscher, P. M. (2019). Improved precision of epigenetic clock estimates across
867 tissues and its implication for biological ageing. *Genome Medicine*, 11(1), 54.
868 doi:10.1186/s13073-019-0667-1
- 869 Zhavoronkov, A., Li, R., Ma, C., & Mamoshina, P. (2019). Deep biomarkers of aging and
870 longevity: from research to applications. *Aging (Albany NY)*, 11(22), 10771-10780.
871 doi:10.18632/aging.102475
- 872 Zou, H., & Hastie, T. (2005). Regularization and variable selection via the elastic net.
873 *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 67(2),
874 301-320. doi:<https://doi.org/10.1111/j.1467-9868.2005.00503.x>





Figure 1. a, Overview of the nested cross-validation approach. MAE = mean absolute error; RMSE = root-mean-square error. **b**, Histogram of the chronological age distribution of the full analytical sample. The statistical mode (age = 61 years) is shown in red. **c**, Distribution of metabolite levels by chronological age, showing scatter plots of all observations and smooth curves (note the difference in y-axis scale). The smooth curves were estimated using generalised additive models, with shaded areas corresponding to 95% confidence intervals. GlycA = glycoprotein acetyls. **d**, Scatter plot showing the hazard ratio (HR) for all-cause mortality and the beta for chronological age associated with a one standard deviation (SD) difference in metabolite levels. Metabolites that had statistically significant associations with both chronological age and all-cause mortality are shown in purple.




Figure 2. **a**, Nested cross-validation mean absolute error (MAE) for all models with tuned hyperparameter values in the 10% hold-out test sets. CV = cross-validation. **b**, Heatmap of Pearson's correlation coefficient (r) between the predicted age values for all models. Estimates shown were multiplied by 100. **c**, Line plot showing the correlation between predicted age and chronological age for all models before (solid lines) and after (dotted lines) applying a statistical correction to the predicted age to remove the age bias (i.e., the systematic overestimation of age in young individuals and underestimation of age in older individuals). **d**, **e**, 2D density plots showing the correlation between predicted age derived from the Cubist rule-based regression model and chronological age before and after age bias correction. Observations beyond y-axis limits of 30 to 80 not shown. **f**, Mean absolute error for all models with tuned hyperparameter values calculated in the full sample after age bias correction. **g**, Density plot showing the distribution of MileAge delta (adj.) for all models. See Panel 1 for model abbreviations.





Figure 3. a, Associations between MileAge delta (adj.) and health indicators for all models. Models were adjusted for chronological age and sex. Reference group: individuals with a MileAge delta (adj.) smaller than one standard deviation below the mean. See Panel 1 for model abbreviations. **b**, Partial effect plots of generalised additive models of the association between health indicators and MileAge delta (adj.). Models were adjusted for chronological age and sex. The shaded areas correspond to 95% confidence intervals.




Figure 4. **a**, Kaplan-Meier plot showing survival probabilities for all-cause mortality by MileAge delta (adj.) derived from the Cubist rule-based regression model. Log-rank test p -value < 0.001 . **b**, Hazard ratios and 95% confidence intervals from Cox proportional hazards models by MileAge delta (adj.) for all models. Models were adjusted for chronological age and sex. Age (in years) was used as the underlying time axis. Reference group: individuals with a MileAge delta (adj.) smaller than one standard deviation below the mean. See Panel 1 for model abbreviations. **c**, Density plot showing the distribution of MileAge delta (adj.) derived from the Cubist rule-based regression model. **d**, **e**, All-cause mortality rate by percentile of chronological age, MileAge (adj.) and MileAge delta (adj.) derived from the Cubist rule-based regression model. **f**, Histogram showing the distribution of MileAge delta (adj.) derived from the Cubist rule-based regression model, stratified by sex. **g**, **h**, Hazard ratios and 95% confidence intervals from Cox proportional hazards models for all-cause mortality by MileAge delta (adj.) derived from the Cubist rule-based regression model, stratified by self-rated health and chronological age group.






Figure 5. a, Hazard ratios (HR) and 95% confidence intervals from Cox proportional hazards models for all-cause mortality by MileAge delta (adj.), the frailty index, grip strength and telomere length. Models were adjusted for chronological age and sex. Age (in years) was used as the underlying time axis. Reference group: individuals with a score smaller than one standard deviation below the mean. **b**, C-index and 95% confidence intervals from Cox proportional hazards models for all-cause mortality for chronological age + sex (the base model) and for each ageing marker added separately to the base model. Time (in days) was used as the underlying time axis. **c**, Log(HRs) and 95% confidence intervals from Cox proportional hazards models for all-cause mortality. Models were adjusted for chronological age and sex. Age (in years) was used as the underlying time axis. Vertical lines indicate the median of the distribution which represents the reference for interpreting the estimates shown.